The difference between domestic and imported Nilotinib

Nilotinib (Nilotinib), an oral inhibitor of Abelson protein tyrosine kinase activity, has been approved for the treatment of patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase and in patients with chronic or accelerated phase CML who may be resistant or intolerant to prior treatments. The difference between domestically produced and imported drugs may lie in different manufacturers, different production specifications, and differences in prices. The pharmaceutical ingredients of domestically produced nilotinib and imported drugs are basically the same. Currently, domestically produced drugs produced by Qilu Pharmaceutical and Terry Pharmaceuticals have been approved for marketing, but the specific price has not yet been determined. The original drug Nilotinib, which is marketed in China, has entered the scope of medical insurance, and the price of each box of 150mg*120 tablets may be around 9,000 yuan.